+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Function, End-User - Forecast 2023-2030

  • PDF Icon

    Report

  • 182 Pages
  • October 2023
  • Region: Global
  • 360iResearch™
  • ID: 5306611
UP TO OFF until Dec 31st 2023
1h Free Analyst Time

Quick Summary:

In the ever-evolving landscape of the pharmaceutical industry, the imperative of monitoring drug safety and efficacy cannot be overstated. The Pharmacovigilance Market is at the heart of this essential practice, providing insights crucial for companies striving to uphold public health standards and adhere to regulatory requirements. Our comprehensive market research report serves as an indispensable resource, elucidating the multifaceted aspects of pharmacovigilance through in-depth analysis and forecasts.

With the sector witnessing a paradigm shift towards more nuanced and meticulous drug monitoring systems, businesses demand clarity on market directions and opportunities to refine their strategies. This report dissects the market's extensive segmentation, revealing significant trends within contract outsourcing, diverse clinical trial phases, and specialized functions like targeted spontaneous reporting. By interpreting these emerging patterns, executives can align their operations with the most lucrative practices and anticipate the future demand curve. Additionally, a focus on the varying roles of end-users from academic institutions to biotech companies provides a panoramic view of the market's stakeholders.

Our market analysis does not merely enumerate statistics; it integrates the FPNV Positioning Matrix and vendor share assessments to gauge competitive dynamics and foster strategic planning. Understanding these landscapes empowers businesses to navigate the market astutely, buttressing their position and maximizing their influence in the pharmacovigilance arena. Detailed profiles of key industry players complement this strategic outlook, offering benchmarks for innovation and market presence.

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Pharmacovigilance Market size was estimated at USD 7.68 billion in 2022, USD 8.86 billion in 2023, growing at a CAGR of 15.74% to reach USD 24.76 billion by 2030.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Pharmacovigilance Market.
  • Based on Type, the market is studied across Contract Outsourcing and In-house. The In-house is projected to witness significant market share during forecast period.
  • Based on Clinical Trial, the market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-Clinical. The Phase III is projected to witness significant market share during forecast period.
  • Based on Function, the market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting. The Targeted Spontaneous Reporting is projected to witness significant market share during forecast period.
  • Based on End-User, the market is studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies. The Academic & Research Institutes is projected to witness significant market share during forecast period.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Pharmacovigilance Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Pharmacovigilance Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Pharmacovigilance Market, highlighting leading vendors and their innovative profiles. These include Accenture, PLC, Bristol-Myers Squibb Company, Capgemini SE, ClinChoice, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA Inc., ITclinical, Laboratory Corporation of America Holdings, Linical Co., Ltd., Novartis AG, Oracle Corporation, Parexel International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited.

The report offers valuable insights on the following aspects:

  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast for the Pharmacovigilance Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Pharmacovigilance Market?
  3. What is the competitive strategic window for identifying opportunities in the Pharmacovigilance Market?
  4. What are the latest technology trends and regulatory frameworks in the Pharmacovigilance Market?
  5. What is the market share of the leading vendors in the Pharmacovigilance Market?
  6. Which modes and strategic moves are suitable for entering the Pharmacovigilance Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Frequently Asked Questions about the Global Pharmacovigilance Market

What is the estimated value of the Global Pharmacovigilance Market?

The Global Pharmacovigilance Market was estimated to be valued at $8.86 Billion in 2023.

What is the growth rate of the Global Pharmacovigilance Market?

The growth rate of the Global Pharmacovigilance Market is 15.7%, with an estimated value of $24.76 Billion by 2030.

What is the forecasted size of the Global Pharmacovigilance Market?

The Global Pharmacovigilance Market is estimated to be worth $24.76 Billion by 2030.

Who are the key companies in the Global Pharmacovigilance Market?

Key companies in the Global Pharmacovigilance Market include Accenture, PLC, Bristol, Myers Squibb Company, Capgemini SE, ClinChoice, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited and ICON PLC.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Pharmacovigilance Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the Prevalence of Chronic Diseases
5.1.1.2. Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
5.1.1.3. Rise in Demand for Outsourcing Services by Players
5.1.1.4. Rising Incidence of ADR and Drug Toxicity
5.1.2. Restraints
5.1.2.1. High-cost Technology for Small and Mid-sized Players
5.1.3. Opportunities
5.1.3.1. Emergence of COVID-19 have Opened New Opportunities
5.1.3.2. Rising Investment in Research and Development (R&D) by Healthcare Companies
5.1.4. Challenges
5.1.4.1. Lack of Skilled Labor
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Pharmacovigilance Market, by Type
6.1. Introduction
6.2. Contract Outsourcing
6.3. In-house
7. Pharmacovigilance Market, by Clinical Trial
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
7.6. Pre-Clinical
8. Pharmacovigilance Market, by Function
8.1. Introduction
8.2. Cohort Event Monitoring
8.3. EHR Mining
8.4. Intensified ADR Reporting
8.5. Spontaneous Reporting
8.6. Targeted Spontaneous Reporting
9. Pharmacovigilance Market, by End-User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Government Agencies
9.4. Health Insurance Companies
9.5. Hospitals & Care Providers
9.6. Pharma & Biotech Companies
10. Americas Pharmacovigilance Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Pharmacovigilance Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Pharmacovigilance Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Accenture, PLC
14.1.2. Bristol-Myers Squibb Company
14.1.3. Capgemini SE
14.1.4. ClinChoice
14.1.5. F. Hoffmann-La Roche AG
14.1.6. GlaxoSmithKline PLC
14.1.7. HCL Technologies Limited
14.1.8. ICON PLC
14.1.9. Infosys Limited
14.1.10. International Business Machines Corporation
14.1.11. IQVIA Inc.
14.1.12. ITclinical
14.1.13. Laboratory Corporation of America Holdings
14.1.14. Linical Co., Ltd.
14.1.15. Novartis AG
14.1.16. Oracle Corporation
14.1.17. Parexel International
14.1.18. Pfizer Inc.
14.1.19. Quanticate International limited
14.1.20. Sanofi S.A.
14.1.21. Syneos Health
14.1.22. TAKE Solutions Limited
14.1.23. TATA Consultancy Services Limited
14.1.24. Wipro Limited
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
FIGURE 2. PHARMACOVIGILANCE MARKET SIZE, 2022 VS 2030
FIGURE 3. PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. PHARMACOVIGILANCE MARKET DYNAMICS
FIGURE 7. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2030 (%)
FIGURE 10. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
FIGURE 12. PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 14. PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 24. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 9. PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 15. PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 41. CANADA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 42. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 45. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 46. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 63. CHINA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 64. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 67. INDIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 68. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 75. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 76. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 99. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 100. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 112. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 116. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 117. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 120. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 121. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 124. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 125. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 128. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 136. ITALY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 137. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 148. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 149. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 152. POLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 153. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 156. QATAR PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 157. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 172. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 184. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 185. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 195. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022
TABLE 196. PHARMACOVIGILANCE MARKET LICENSE & PRICING

Companies Mentioned

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

Methodology

Loading
LOADING...